Dermatofibrosarcoma protuberans: lines of therapy
5 standard-of-care settings across 3 lines and 1 biomarker subgroup. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.
Early / localised
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Localised disease | Wide local excision with 2 to 3 cm margins to fascia, or Mohs micrographic surgery with complete circumferential margin assessment; re-excision for involved margins. | NCCN Guidelines: Dermatofibrosarcoma Protuberans | - | |
| All comers | Neoadjuvant | Imatinib for several months to shrink large or facial tumours before excision. | NCCN Guidelines: Dermatofibrosarcoma Protuberans | 78 |
Advanced, first line
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Unresectable, recurrent or metastatic disease | Imatinib after confirming the COL1A1-PDGFB fusion (EORTC 62027 and SWOG S0345); surgery after response where feasible. | NCCN Guidelines: Dermatofibrosarcoma Protuberans | 78 | |
| All comers | After imatinib failure or fibrosarcomatous metastatic disease | Sunitinib or pazopanib; sarcoma-type chemotherapy with doxorubicin for metastatic fibrosarcomatous disease. | NCCN Guidelines: Dermatofibrosarcoma Protuberans | 90 |
Other settings
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Positive margins not amenable to further surgery | Adjuvant radiotherapy to the tumour bed. | NCCN Guidelines: Dermatofibrosarcoma Protuberans | 93 |
Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.